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ABSTRACT 
 Iron is necessary in fetal development, however little research has been 
conducted to assess factors that affect both maternal and fetal total body iron.  The 
objective of this research is to investigate infant iron status at birth and 4 months of 
age in relation to the factors affecting maternal iron status. 
Pregnant subjects (n=350) between the ages of 16 and 35.99 and a BMI < 40 
were recruited between 8 and 20 weeks gestational age to consume DHA or placebo 
capsules.  This analysis is secondary to the primary research. Post-partum and cord 
blood samples were collected at birth and an additional sample was collected from the 
infant at 4 months of age.  Transferrin receptor and ferritin were analyzed from all 
blood samples obtained.  Maternal and infant medical records were also followed 
along with subject report to gather information on factors that may affect iron status.  
Correlations between maternal body iron and cord blood; and maternal body iron and 
4 month infant body iron were obtained through bivariate correlations.  Linear 
regression assessed covariates that affect cord blood and infant iron status. 
 Smoking before pregnancy, high blood pressure during pregnancy, and infant 
gender were all found to significantly affect the infant total body iron in the cord 
blood sample (p<0.05).  Infant total body iron at birth was also correlated with 4 
month infant body iron (p<0.05).  This study reaffirms previously published research 
that infant and maternal iron status are affected by smoking, high blood pressure, and  
infant being male gender.
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Chapter 1 
INTRODUCTION 
 Iron is necessary in fetal development of brain tissue, auditory and visual 
systems, and the immune system.  Research shows that fetuses receive iron 
preferentially from the mother (1).  However, little research exists concerning factors 
relating to maternal iron status and relationship to infant iron status.  The present 
body of literature focuses on factors that affect maternal iron status or iron 
supplementation and infant iron status alone. Zhou et al. (2) reported that maternal 
iron supplementation was not correlated with infant iron status at either six months or 
4 years of age. Iron status of infants whose mothers were supplemented with iron did 
not differ from those whose mothers received a placebo.  However, these researchers 
found a positive correlation between iron supplementation and decreased incidence of 
iron deficiency and iron deficiency anemia in mothers (2).   
 Hemoglobin and hematocrit are frequently used indicators of iron status that 
can determine iron deficiency anemia only after iron deficiency has developed (3). 
These are the primary indicators of iron status that have been measured in studies of 
infants and mothers.  Body iron can be determined calculated by using both plasma 
transferrin receptor and ferritin and both are the currently accepted means of 
identifying iron status (4).  Physiologically, serum transferrin receptor increases as 
stored iron decreases, while serum ferritin is used to store and transport iron and 
decreases when iron stores are low (5). Few studies have measured iron status in 
infants and mothers using the body iron method (6)
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 Many factors are involved in the iron status of pregnant women.   The major 
factors associated with variable iron status are ethnicity, BMI, smoking, and parity.   
Increases in blood volume during pregnancy make physiologic anemia and iron 
deficiency anemia difficult to determine, particularly in late pregnancy (7). 
 Even though it is well known that the mother is the source of iron for the 
fetus, the evidence linking maternal iron status to the newborn infant is weak.  
Published data do not demonstrate strong relationships between newborn iron status 
and factors affecting maternal iron status.  Much of the published research used 
hemoglobin and hematocrit to assess iron status and these are not specific measures 
of iron status.  Studies comparing maternal and newborn body iron might better 
indicate a relationship between maternal and newborn iron status. 
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Statement of Purpose 
The purpose of this research is to investigate infant iron status at birth and 4 months 
of age in relation to maternal iron status and factors that affect maternal iron status. 
 
Research Questions 
1. What is maternal body iron, newborn (cord blood) and infant (4-month-old) 
body iron in the cohort enrolled in the Kansas University DHA Outcomes 
Study? 
2. What are the relationships among maternal body iron at delivery, newborn 
(cord blood) and infant (4-month-old) body iron? 
3. Are the relationships between maternal and newborn or maternal and infant 
body iron influenced by mothers’ baseline hemoglobin, postpartum body iron, 
ethnicity, BMI, smoking, parity, and postnatal feeding?   
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Chapter 2 
 
LITERATURE REVIEW 
 
Prevalence of Iron Deficiency 
 Iron deficiency is a global problem. It is estimated that 1.2 billion people 
worldwide are iron deficient; however, iron deficiency is less common in the United 
States (8).  Thirty to fifty percent of pregnancies worldwide are iron deficient and the 
high prevalence of iron deficiency may be related to lasting developmental effects in 
infants (9). It is recommended by the World Health Organization that food be 
supplemented with ferrous sulfate, ferrous fumarate, ferric pyrophosphate, or 
electrolytic iron powder because they have the best bioavailability (10).  US National 
Health and Nutrition Examination Survey (NHANES) data show that iron deficiency 
is greatest in children one to two years of age (7%) and in females of child bearing 
age (12-49 years).  The prevalence of iron deficiency is two times higher among US 
African Americans and Hispanic-American females than non-Hispanic whites (8).  
The recommended dietary allowance is 27 mg per day of iron for pregnant women to 
prevent iron deficiency, (11).  NHANES data suggests that the mean iron intake 
among pregnant women is 15mg per day (8). 
 
Iron Absorption  
 Iron absorption is primarily regulated by body iron stores with the duodenum 
being the primary site of absorption.  When the body’s demand for iron is increased, 
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absorption is also increased (12).  Iron homeostatsis is regulated by hepcidin 
produced in liver and adipose tissue (13). 
 There are two forms of iron from the diet.  Heme iron is the most bioavailable 
source of iron and is only available in animal products.  Vitamin C is believed to aid 
absorption of non heme iron by facilitating extraction of iron from food and 
preserving it as a soluble, low molecular weight form.  Iron then must be converted to 
reduced ferrous iron for absorption in the intestine to occur.  Factors that aid this 
conversion include: gastric pH and organic acids, mucus, redox reactions, and 
intestinal transit time. Dietary factors that inhibit iron absorption include: phytates, 
polyphenols, calcium, and some proteins (casein, whey, egg white, and soy) (12).   
 Ninety percent of the body’s daily iron needs are met by recycling red blood 
cells; the remaining 10% must come from the diet or supplements.  During 
pregnancy, additional exogenous iron is needed due to fetal demands and plasma 
volume changes (13). During the total pregnancy, 300 mg of iron is needed for the 
fetoplacental unit.  Maternal hemoglobin mass expansion requires about 800 mg of 
iron; and about 200 mg of iron is lost from the gut, urine, and skin during the total 
duration of pregnancy (14).  A majority of the iron is needed during the third 
trimester of pregnancy due to rapid growth of the fetus (9). 
  
Fetal iron acquisition 
 There are mixed data relating to the ability of the fetus to obtain adequate iron 
stores with mild to moderate maternal iron deficiency.  It is known that the fetus 
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receives most nutrients preferentially.  Nevertheless, O’Brien et al. (1) reported that 
iron transfer was related to maternal stores,  suggesting that increased maternal iron 
stores would correlate with better fetal iron status (1). 
 Maternal iron is bound to transferrin and transferred to the fetus by transferrin 
receptors on the apical surface of the placental cells.  The iron that is taken up is 
transferred to apotransferrin on the fetal side of the placenta and from there to fetal 
circulation as halotransferrin (10).  In a study by O’Brien et al (1), 41 pregnant 
women ages eighteen to thirty-five, received radioactive iron tracer or a placebo.  
Amounts of tracer were then measured in the infant cord blood and serum.  It was 
found that the transfer of non-heme iron to the fetus was significantly greater if the 
mother did not receive iron supplementation.  The study also suggested that dietary 
iron was transferred rapidly to the fetus and little iron tracer was remobilized and 
transferred to the fetus from maternal stores.  A significant positive correlation was 
seen with higher maternal iron concentration and the increased transfer of oral iron 
tracer.  Serum ferritin indicated maternal iron stores and was a strong inverse 
predictor of transfer of oral iron tracer to the fetus; there was a significantly greater 
amount of fetal iron tracer in infants born to iron deficient mothers.  Poorer iron status 
in the fetus as evidenced by lower cord ferritin and hematocrit was associated with 
more tracer transferred to infants (1).  This finding demonstrates that iron transfer to 
the fetus is dependant on maternal iron status. 
 Iron needs for the fetus increase during the third trimester. Approximately 1-
1.5 mg of iron is required per day before pregnancy and this is increased to greater 
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than 6 mg per day in the third trimester.  To meet these needs, it is usually necessary 
to provide supplemental iron (1).  If the fetus does not receive adequate iron, iron 
decreases first in the reticuloendothelial system (placenta and fetus), and then in the 
heart and brain (9). 
 The total body iron content of full term infants is approximately 75 mg/kg 
with 60% of the iron accumulated in the third trimester.  About 75-80% of body iron 
is found in hemoglobin, 10% in tissues as iron containing proteins, and the remaining 
10-15% stored in ferritin and hemosiderin. 
 
Assessment of iron status 
 There is not a single laboratory test to assess iron status in all compartments 
(red blood cell, transport, functional, and storage) (9).  It is common to use 
hemoglobin or hematocrit.  Serum ferritin is a more specific measure because it 
shows anemia caused by iron rather than other nutrients (15).  The “gold standard” 
for iron status is stained aspirate of bone marrow for hemosiderin.  However, this 
technique is invasive and is not used to screen for iron deficiency in pregnant women 
(5).  It is becoming more common to use total body iron calculation using serum 
transferrin receptor and ferritin Both are specific measures of iron status (16). 
 Many techniques used to assess iron status in pregnancy are not accurate 
measures of iron status.  Hemoglobin is only a measure of the degree of iron 
deficiency once anemia has developed.  It is also unreliable during pregnancy due to 
hypervolemia and changes in red blood cell mass.  Total iron binding content and 
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immunochemical transferrin are good measurements of iron status; but they may not 
be appropriate measurements during pregnancy due to inflammation.  Mean 
corpuscular volume is not an accurate measure of iron status because it can be 
influenced by other nutrients/factors and therefore is not a sensitive measurement.  
Serum iron is not a quality measurement of iron status due to diurnal variation (5).   
 Zinc protoporphyrin (ZPP) can be used to measure iron status and increased 
ZPP levels suggest incomplete incorporation of iron into protoporphyrin.  ZPP is 
regarded as a sensitive iron indicator.  Serum ferritin has been found to be the best 
single indicator, but it can be artificially elevated by inflammation.  It is best to use a 
mixture of values including ferritin, transferrin receptor, and reticulocyte hemoglobin 
which are true measures of iron status (5).   
 Non-anemic women can have normal ferritin values between 20-300 μg/L.  
Women with anemia can have levels less than 20 μg/L, however serum ferritin values 
as high as 37 μg/L have been observed in anemic women.  When assessed in 
comparison to hemosiderin, den Broek (17) reported that the optimal cut-off point for 
serum ferritin to assess anemia in pregnant women was 30 μg/L or less(17). 
 Total body iron calculation is an accurate and non-invasive way to calculate 
iron stores.  This method is calculated using a ratio of transferrin receptor to ferritin, 
the equation is as follows: body iron (mg/kg)=[log(R/F ratio)-2.8229]/0.1207. Total 
body iron calculation is a reliable method to detect mild iron deficiency in a healthy 
population where chronic infection, inflammation, and liver disease does not exist 
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(16).  Cook et. al has demonstrated iron deficiency anemia occurs when total body 
iron goes below -4 mg/kg (18). 
 Scientific reports indicate the use of different indicators to determine iron 
deficiency.  Siddappa used a serum ferritin of less than or equal to 34 μg/L for 
evaluating suspected brain iron deficiency (19).  Algarin defined iron deficiency 
anemia as having two of the three iron identifiers, mean corpuscular volume less than 
70fL, erythrocyte protoporphyrin greater than 100 μg/L, red blood cell less than 1.77 
μM, serum ferritin less than 12 μg/L, hemoglobin less than or equal to 10 mg/dL at 
six months or less; or 11 mg/dL at 12 & 18 months of age (3). 
 
Physiological functions of iron 
 In iron deficiency anemia, microcytic, hypochromic red blood cells and low 
hemoglobin are evident.  If the diet does not supply adequate iron, iron is taken from 
ferritin or storage iron.  During this time, ferritin decreases and transferrin receptors 
increase.  Next, iron is taken from hemoglobin and iron metalloenzyme causing a 
decrease in these values.  When the body is using ferritin stores, hemoglobin may 
remain in the normal range, called iron deficiency without anemia.  After a prolonged 
period of time, hemoglobin synthesis is slowed and hemoglobin concentration will 
decrease.  There are many changes in hemoglobin after birth, for this reason, age-
specific values need to be used to define anemia.  After birth, the infant hemoglobin 
decreases by 30-50% related to decreased erythropoiesis, lysis of senescent fetal red 
blood cells, and expansion of vascular volume.  Preterm infants miss the normal 
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accumulation of fetal iron and are at risk for iron deficiency (9).  Hemoglobin can 
drop to less than 10 g/dL in infants and is still considered in normal range (20). 
 During pregnancy, there are changes in plasma volume, increased 
erythropoiesis, and increased demands of the fetoplacental unit for iron (17).  Iron 
deficiency is more common than iron deficiency anemia in the later stages of 
pregnancy and even occurs in women who begin pregnancy with adequate iron stores.  
Hemoglobin is an indicator of iron deficiency anemia, hemoglobin is typically 
microcytic and hypochromic.  This is because a majority of iron transfer to the fetus 
occurs after 30 weeks of gestation when maternal iron absorption is most efficient 
(10). 
 Maternal hemoglobin and hematocrit decrease throughout the first and second 
trimesters and reach the lowest point early in the third trimester.  Both values 
normally rise closer to term.  Risk for anemia may need to be detected early in 
pregnancy because physiologic anemia and iron deficiency anemia are difficult to 
discern in late pregnancy (4).  Iron supplementation during pregnancy significantly 
improves maternal hemoglobin when iron deficiency is present (7), however 
supplementation has not been found to affect fetal body iron (21). 
 
Iron and cognitive and intellectual development 
 The liver and brain have the highest concentration of iron during the first 
trimester. This is a critical time of brain development in the fetus, and the increase 
suggests an important role of iron in cognitive development (22). 
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 A study of Indian women showed that lower maternal hemoglobin 
concentrations were correlated with lower infant Apgar scores and higher risk of 
infant asphyxia (10).  A study comparing full-term infants with anemic infants 
reported that the infants with better iron status scored 6-15 points higher on mental 
development tests.  Toddlers at 3-4 years of age continued to have lower mental 
development if they were iron deficient in infancy (23). 
 Effects of iron deficiency during development can be found beyond infancy.    
Neurocognitive abnormalities have been found in previously iron deficient infants at 
6-24 months of age (24).  Adolescents (11-14 years of age) who were treated for 
severe iron deficiency as infants tested lower in math, writing achievement, and 
motor function.  These adolescents had behaviors that were viewed as problematic 
including: anxiety/depression, social problems, and attention problems.  In a state-
wide Florida study, anemia during infancy based on hemoglobin screening in Women 
Infants and Children (WIC), was related to special education placement at ten years 
of age (23). 
 
Iron and auditory and visual development 
 Iron is required for normal auditory development.  One theory is that impaired 
myelination caused by iron deficiency may result in delayed auditory recognition as 
suggested by the correlation with the time of deficiency and period of rapid myelin 
production (19). Siddappa et al. (19) observed that neonatal auditory recognition 
memory processing was lower in iron deficient infants than iron sufficient newborns.  
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This study determined iron deficiency as a neonatal serum ferritin concentration of 
less than 34 μg/L (19).  At four years of age, the children who had iron deficient 
anemia at birth had longer auditory brainstem response and lower visual evoked 
potentials compared to infants without iron deficiency anemic (3). 
 
Infection 
 Iron plays a vital role in the immune system.   It is well known that infants and 
children are prone to illness, particularly upper respiratory infections.  Having good 
iron stores is most likely beneficial in preventing infection.  Mullick et al. (25) found 
that iron deficiency anemia correlated with decreased T-lymphocytes when compared 
with non-anemic children.  With supplementation of iron, T-lymphocyte counts 
significantly improved, thus implying the children’s immune system and resistance to 
infection improved (25). 
 In an observational study by Levy et al (15), iron deficient anemic children 
were found to have a significant increase incidence of diarrhea and respiratory 
infection when compared to non-anemic children (15).  It can be inferred that since 
iron status is related to the incidence of infection and the immune system in children, 
iron status also plays a role in the immune system of infants. 
 
Maternal iron status and infant outcomes 
 Maternal iron status is normally assessed with hemoglobin and hematocrit.  It 
was once thought that deleterious effects of iron deficiency did not occur unless 
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anemia was present.  It is now known that many organs show morphological, 
physiological, and biochemical changes before a drop in hemoglobin is observed 
(22).  Infants are at risk for iron deficiency because of rapid growth and limited 
dietary sources of iron (3). 
 Studies have shown if women enter pregnancy with low iron stores, iron 
supplements may not prevent iron deficiency anemia (10).  Infants born to iron 
deficient mothers are at risk for iron deficiency throughout infancy, even if it appears 
the infant is consuming enough iron.  It has been found that maternal hemoglobin less 
than 8.5 mg/dL is related to a decrease in fetal iron stores (9).   
 
Relation of maternal iron status to infant status 
Two different studies, in France and Turkey, found that serum ferritin at two months 
of age was associated with maternal iron status (10). Most literature examines 
hemoglobin rather than body iron.  Many studies with diverse populations have 
demonstrated that maternal hemoglobin is not correlated with fetal cord blood 
hemoglobin.  Decreased hemoglobin in the second and third trimester is related to 
increases in plasma volume throughout pregnancy rather than iron deficiency (4).  A 
study in Britain found that infants born to non-anemic mothers compared to infants 
with anemic mothers had more positive outcomes such as higher blood volume, red 
blood cell volume, and circulating hemoglobin mass (10). 
 
 
 
14 
 
 
Maternal iron status related to infant outcomes 
 Iron deficiency anemia early in pregnancy has been correlated with increased 
risk for small for gestation age (SGA) and preterm delivery.  Risk for preterm 
delivery was increased when iron deficiency anemia occurred early in gestation or the 
first trimester; but not when it occurred in the second or third trimester (4).  In a study 
with non-anemic women, incidence of low infant birth weight was reduced with 
routine iron supplementation (5).  
 
Breast feeding and infant iron status 
 Iron content is highest in human milk during early transitional milk (0.97 
mg/dL) and decreases as the infant grows, reaching about 0.3 mg/dL by five months 
of age.  At one month, infants ingest about 0.075 mg/kg iron, 0.055 mg/kg at two 
months, and 0.048 mg/kg at three months.  Breast milk iron concentration does not 
appear to be affected by mothers iron status or maternal supplementation.  Iron 
deficiency anemia has been observed in 10% of infants who weighed greater than 
3kg, 50% in infants who weighed less than 3kg who were breast fed (26). Children 
born without iron deficiency or iron deficiency anemia who are exclusively breast fed 
have better iron status at four months of age (95% GI:0.04, 0.90) (5).  Based on 
calculations, it is expected that human milk provides adequate iron until six months of 
age in a healthy weight infant (1).  The relationship between maternal iron status and 
infant iron status is more difficult to determine when infants are fed iron fortified 
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formula/food from an early age (10).  The American Academy of Pediatricians 
recommends iron supplementation at 1 mg/kg by four to six months in breast fed 
infants (27). 
 
Ethnicity in relation to maternal iron deficiency 
 African American and Hispanic women are at the greatest risk for iron 
deficiency.  The NHANES data show that Hispanic women of childbearing age are 
2.8 times more likely to be iron deficient and 2.9 times more likely to have iron 
deficiency anemia respectively.  The study used the markers of serum ferritin 
concentration, transferrin saturation, erythrocyte protoporphyrin, and hemoglobin.  
Mexican American females were also more likely to have lower mean hemoglobin, 
transferrin saturation, and serum ferritin while mean erythrocyte protoporphyrin was 
significantly higher.  It should be noted that Mexican American and non Hispanic 
American women had similar intakes of iron and that both groups had intake below 
the recommended intake levels for the United States (16).   
 Similar findings have been demonstrated in African-American women (8). 
Young low income black women in the United States were three times more likely to 
have small for gestational age (SGA) and preterm delivery if they were iron deficient 
in the first trimester of pregnancy (10).   
 
BMI in relation to maternal iron deficiency 
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 Obesity and overweight during pregnancy are also associated with risk for 
poor iron status during pregnancy (28, 29).  A mechanism for why BMI may have an 
effect on iron stores in pregnancy has not been extensively researched.  Differences in 
dietary intake have been implicated by Laraia et al. (30) and found that as BMI 
increased, the women who did not meet the estimated adequate intake for iron also 
increased (30). 
 
Smoking and iron status 
 Maternal iron deficiency may be masked in smoking mothers because 
hemoglobin may be normal due to the increased need for hemoglobin to supply 
adequate oxygen to cells.  Rao et al. (9) reported that women who smoke need extra 
iron in addition to iron requirements for pregnancy.  Smoking can cause intrauterine 
fetal hypoxia, and changed erythropoiesis requiring additional iron (9).  The 
relationship to smoking and decreased iron status has been well researched; however 
current studies are observational because it is unethical to prescribe smoking. 
 
Parity and iron status 
 The number of prior pregnancies is inversely related to iron stores and the 
chance of iron deficiency increases with each pregnancy.  This may be because 
maternal iron stores are used during pregnancy to support fetal development.  
Mothers with no previous pregnancies were found to have higher serum ferritin than 
mothers with previous pregnancies.  As the number of pregnancies increased, mean 
 
17 
 
serum ferritin decreased (31).  Compared to women with no previous pregnancy, 
those with two or more children were three to four times more likely to develop iron 
deficiency (7).  
 
Conclusion 
 Iron deficiency is still a problem among U.S women even though iron 
supplementation is practiced.  Pregnant women are at greater risk for iron deficiency 
because of increased need.  Iron deficiency is detrimental to cognitive, auditory, 
visual, and immune function in the developing fetus.  Better maternal iron status 
correlates with better fetal iron stores and improved infant development. 
 Many factors may be related to maternal iron status including ethnicity, BMI, 
smoking status, and parity.  Evidence is still inconclusive regarding maternal iron 
stores and their affect on infant iron status, especially later in development of the 
infant and child.  More research is necessary to assess the greatest risk factors 
affecting maternal iron status and its impact on infant body iron. 
 
18 
 
 
Chapter 3 
METHODS 
 
Overview 
 
 The primary purpose of the Kansas University DHA Outcomes Study was to 
investigate the effects of DHA supplemented during pregnancy on the cognitive and 
visual development of children.  The research below is a secondary analysis that will 
examine the relationship between factors that affect maternal iron status and body 
iron in newborn and four month old infants.  
Setting 
 The study was conducted at the University of Kansas Medical Center and all 
subjects lived in the Kansas City Metro area.  The study duration was from January 
2006 and follow-up is still being performed on children.  Subjects were recruited 
from three hospital sites including St. Luke’s Plaza, Truman Medical Center, and the 
University of Kansas Medical Center.  Subjects were also recruited through word of 
mouth.  Interested participants recruited from St. Luke’s Plaza, Truman Medical 
Center, and word of mouth were required to come to the University of Kansas 
Medical Center to enroll in the study.  Mothers recruited from the University of 
Kansas Medical Center could enroll on the spot in the obstetrics and gynecology 
clinic. 
 Study personnel would visit mothers receiving prenatal care at University of 
Kansas Medical Center in the OB clinic.  Subjects were not visited at antenatal 
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appointments if they received prenatal care from another clinic.  Contact was 
maintained with all subjects through phone, email, and written correspondence. 
Sample 
  Subjects (n=350) were enrolled if they met the inclusion criteria for a study 
on the effects of DHA on pregnancy outcome. Recruiting took place from January 2, 
2006 thru November 17, 2009.  Signs explaining the study were in waiting areas for 
mothers to view.  Recruiters screened mothers based on age, BMI, gestation duration, 
and medical history.  Pregnant women were enrolled if they were between 16-35.99 
years of age with a BMI less than 40 and between 8 and 20 weeks gestation at 
enrollment.  Women were excluded if they did not speak English, had pre-existing 
diabetes or hypertension, or were carrying more than one fetus.  Women were also 
excluded if they had a chronic illness that could affect the planned outcomes of the 
primary clinical trial.  If a woman was eligible, she was asked for permission to be 
told about the study and decided if she wished to enroll. 
 Subjects from the primary research study were excluded for this investigation 
if a postpartum blood sample was not obtained.  Also, to be included in the analysis 
the subject had to have at least one combination of pairs; postpartum maternal blood 
and infant cord blood or postpartum maternal blood and 4 month infant blood 
samples. 
 This research investigation was submitted to the Human Subjects Committee 
and the secondary analysis is covered under the primary research study.  All subjects 
signed a consent form to participate in the investigation (Appendix A). 
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Procedures 
 Recruiters reviewed the consent form in detail with the subject before signing 
the consent form.  Information concerning the subjects’ pregnancy history, smoking 
and alcohol intake, medical history and medication intake, supplement use, and a 
food frequency questionnaire created for the investigation was gathered at enrollment.  
Height, weight, and blood pressure were gathered from the subject’s medical records.  
Information from medical records and patient reports was recorded in the study 
database.  Medical records were followed throughout pregnancy and post delivery 
until the infant reached 18 months of age. 
 At enrollment, a baseline blood sample was collected by a trained 
phlebotomist.  Blood was drawn from the anticubical vein in an EDTA tube and 
placed on ice.  Blood was separated to plasma and red blood cells by centrifugation 
within 24 hours of the blood draw.  Red blood cells and plasma were separated and 
plasma was frozen and then later thawed to measure DHA levels.  
Blood samples were collected at birth from the umbilical cord and from the 
mother, then later from the infant at four months of age.  DHA in plasma was 
analyzed as described above for baseline blood samples.  The remaining plasma was 
refrozen and then later analyzed to measure transferrin receptor and serum ferritin 
levels.  Transferrin receptor was measured using Ramco Laboratories, Inc. TFR-94 
and ferritin was measured with Ramco Laboratories, Inc. T-13 testing supplies.  
 
21 
 
Procedures for transferrin receptor are described in Appendix B and ferritin is 
described in Appendix C.  
 All transferrin receptor and ferritin analysis were conducted between April 21, 
2010 and September 8, 2010.  Seventeen samples were run in total and serum 
transferrin receptor and ferritin were tested in duplicate on each sample. 
Materials 
 Data were gathered through the case report (Appendix D) form and from 
medical records.  Transferrin receptor and serum ferritin were measured with kits 
from Ramco laboratories described above.   
Statistical analysis 
 Statistical analysis was performed with SPSS 18.0 software.  The correlations 
between maternal body iron and cord blood and maternal body iron and 4 month 
infant body iron were obtained through bivariate correlations.  Factors that affect 
maternal iron status were examined using linear regression on maternal body iron and 
cord blood; and 4 month old infant body irons and the covariates.    Pearson’s 
correlations of greater than 0.20 were considered significant.  Otherwise a 
significance factpr of p<0.05 was considered significant. 
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Chapter 4 
RESULTS 
Demographics 
  The mean age of subjects was 25.8 years of age with a mean gestational age 
of 14.6 weeks at enrollment.  At the time of enrollment, this was the first pregnancy 
for 38% of subjects.  It was the second pregnancy for 30%, third pregnancy for 17%, 
fourth pregnancy for 7%, fifth pregnancy for 5%, sixth pregnancy for 2% of the 
subjects, and 2% of subjects it was their seventh or eighth pregnancy.  Women had a 
mean BMI of 26.9 at enrollment indicating the overweight category for BMI.  A total 
of 31% participants were African American, 67.7% were Caucasian, 6.8% Hispanic, 
and 1.2% classified themselves as other (see Table 1). 
TABLE 1 
 Parity and ethnicity of subjects 
 
 
 
 
 
 
 
 
Parity N (%) 
  Gravid 1 92 (38%) 
 Gravid 2 73 (30%) 
 Gravid 3 42 (17%) 
 Gravid 4 16 (7%) 
 Gravid 5 12 (5%) 
 Gravid 6 4 (2%) 
 Gravid 7 2 (1%) 
 Gravid 8 1 (1%) 
Ethnicity  
 African American 76 (31%) 
 Caucasian 149 (68%) 
 Hispanic 14 (7%) 
 Other 3 (1%) 
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At the time of delivery, the mean gestational age was 39.43 weeks with a 
mean birth weight of 3362.8 g.  Five percent of the subjects had preterm deliveries 
(<37 weeks gestational age) (n=12). Information concerning breastfeeding was 
gathered at infant follow-up visits, see Table 2 for breastfeeding characteristics of 
subjects. No statistically significant correlations were found with breast feeding 
versus formula feeding in infants total body iron at four months of age. 
 TABLE 2 
Breastfeeding  
 
 
 
 
Body iron status 
  The mean maternal, cord blood, and 4 month infant body iron are displayed 
in Table 3.  Seventeen percent of women (n=43) had negative total body iron at 
delivery.  Of these forty-three subjects, eight may have had iron deficiency anemia 
because they had a total body iron of <-4 mg/kg.  One infant had a negative total body 
iron from the cord blood sample (-0.0336 mg/kg).  At four months of age, 2 infants 
(2%) had a negative total body iron, total body iron was -3.763 mg/kg and -0.483 
mg/kg for these infants.  Maternal body iron was not found to be correlated to the 
infant’s body iron at birth or at four months of age (p > 0.05), however, a statistically 
 N (%) 
0-6 days BF 22 (31%) 
7-42 days BF 14 (20%) 
43-120 days 8 (11%) 
121+ days BF 26 (37%) 
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significant correlation was found between the cord blood and the infants body iron at 
four months of age (p=0.017).  Smoking prior to pregnancy, high blood pressure 
during pregnancy, and infant gender were correlated with total body iron in infant 
cord blood (see Table 4).  The following variables were not found to affect infant 
cord blood body iron: parity, smoking during pregnancy, alcohol consumption, BMI, 
preeclampsia, gestational diabetes, ethnicity, hemoglobin, birth weight, or gestational 
age at delivery (p>0.05) (see Table 4 & 5).  No significant correlations of the above 
factors were found to affect four month body iron (p>0.05) with the exception of 
infant gender (p>0.001). 
 
TABLE 3 
Mean body iron of subjects 
 
TABLE 4 
 
Maternal factors and the correlation to maternal and cord blood or maternal and 4 
month infant iron 
 
 Mean±SE Range N R-Value 
Maternal Body Iron 
(mg/kg) 
4.35±4.04 -6.85 - 14.95 242 1 
Cord Blood Body Iron 
(mg/kg) 
8.25±2.64* -0.03 - 14.86 164 0.036 
4 month Body Iron 
(mg/kg) 
6.27±2.69* -3.76 - 12.42 100 -0.141 
 * Statistically significant at 0.017  
 Maternal & Cord Blood Pairs Maternal & 4mo. Infant Pairs 
 
N 
Total 
N 
R-value P-value N 
Tota
l N 
R-value 
P-
value 
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Smoking during 
pregnancy 
77 163 -0.123 0.116 45 95 0.102 0.314 
Smoking before 
pregnancy 
64 163 -0.153 .050 35 95 -0.004 0.967 
Alcohol use 
before pregnancy 
90 163 -0.152 0.052 62 95 -0.093 0.356 
Alcohol use 
during 
pregnancy 
2 163 -0.028 0.722 0 95 --- --- 
High Blood 
Pressure 
28 162 -0.227 0.003* 19 94 0.038 0.710 
Preeclampsia 
current 
pregnancy 
2 163 -0.007 0.926 3 95 0.047 0.643 
Preeclampsia 
previous 
pregnancy 
3 163 -0.024 0.760 2 95 0.150 0.136 
Gestational 
Diabetes 
8 163 0.048 0.545 4 94 0.073 0.472 
Ethnicity n/a 163 0.158 0.043* n/a 95 0.154 0.127 
Iron 
Supplementation 
47 163 -0.053 0.498 26 95 0.031 0.763 
Iron Supplement 
Taken 
33 163 -0.067 0.396 20 95 0.121 0.229 
Prenatal Vitamin 
During 
Pregnancy 
160 163 0.056 0.478 92 95 0.011 0.917 
Vitamin Prior to 
Pregnancy 
59 163 0.121 0.121 40 95 0.079 0.434 
Infant Gender 
(male) 
70 163 0.188 
0.016*
* 
50 95 0.338 
0.001*
** 
Preterm Delivery 
(<37 weeks) 
7 163 0.120 0.126 5 95 0.000 0.997 
Breastfeeding 
Duration 
n/a n/a 0.072 n/a 48 94 0.005 0.961 
* Statistically significant at p<0.01 
** Statistically significant at p<0.05 
*** Statistically significant at p<0.001 
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TABLE 5 
Maternal factors and the correlation to maternal and cord blood or maternal and 4 
month infant iron 
   
 Parity was correlated with maternal body iron at birth.  High blood pressure, 
initial hemoglobin, iron supplementation, prenatal vitamin intake, vitamin intake prior 
to pregnancy, and weight gain were all correlated with maternal body iron at birth, 
but not infant total body iron at birth (p<0.05). 
 Maternal & Cord Blood Pairs Maternal & 4mo. Infant Pairs 
 Mean±SD N 
R-
value 
P-
value 
Mean±SD N 
R-
Value 
P-
value 
Parity 
(Gravid) 
2.26±1.43 163 0.088 0.262 2.1±1.26 95 -0.065 0.52 
Maternal 
BMI 
(kg/m
2
) 
26.9±5.16 163 0.023 0.774 27.3±4.85 95 0.035 0.731 
Initial 
Hemoglo
bin 
(mg/dL) 
12.6±0.98 162 -0.032 0.69 12.6±0.89 94 -0.038 0.709 
Gestation
al Age at 
Delivery 
(# weeks) 
39.4±1.43 163 -0.093 0.234 39.4±1.52 95 0.132 0.19 
Weight 
Gain 
(pounds) 
27.7±12.67 163 0.079 0.079 28.53±13.45 95 0.806 0.806 
Birth 
Weight 
(g) 
3328.4±49
1.50 
162 -0.059 0.452 3349.2±479.81 95 0.183 0.068 
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Chapter 5 
DISCUSSION 
 Few studies have examined the relationship between maternal and infant total 
body iron. As demonstrated in this investigation as well as other research, 
hemoglobin was not related to maternal or cord blood total body iron at birth.  These 
results show that hemoglobin is not a good indicator of iron status in pregnant women 
and total body iron needs to be used.  This investigation found that smoking before 
pregnancy, high blood pressure during pregnancy, ethnicity, and infant gender are 
significantly correlated to both maternal and infant cord blood body iron assessment.  
These are not novel findings nor were they found to be related to infant body iron at 
four months of age (16), (8).  The only factor that remained significantly correlated to 
4 month total body iron was the infant gender (p<0.001). 
 Cord blood total body iron was correlated to 4 month infant body iron 
(p=0.017).  This finding demonstrates that infant iron status at birth has lasting effects 
into infancy.  Factors such as iron fortified formulas and breast feeding may not 
change the infants iron status at 4 months of age (9, 20). 
 Some observations were made that were nearing significance.  Maternal 
weight gain was nearing significance at p=0.079.  Maternal alcohol use before 
pregnancy neared significance at p=0.052.  These results were likely not significant 
because the study was not designed or powered to answer the secondary research 
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questions.  Previous studies have found maternal weight gain and alcohol use before 
pregnancy to be negatively correlated with infant iron status (9). 
 Gestational age, high blood pressure during pregnancy, baseline hemoglobin, 
prenatal vitamin intake during pregnancy, vitamin intake prior to pregnancy, and 
maternal weight gain during pregnancy were all found to be significantly correlated to 
maternal total body iron at delivery (p<0.05 for all variables).  Previous research has 
correlated these variables to maternal iron status (8). 
 One limitation of this study is that the study was not designed to investigate 
maternal and infant iron status as the primary outcomes.  It would be beneficial to 
have maternal total body iron at baseline to compare to postpartum and infant total 
body iron.  Research has shown that iron status in the first trimester is a better 
predictor of infant iron status (4).  Also, this study was observational and placing all 
mothers on an iron supplement or a specific PNV may better assess iron status.  
Subjects were allowed to take a PNV of their choosing. 
Implications of this study are that total body iron is a more sensitive 
assessment of iron status than hemoglobin and hematocrit.  Physicians should use 
transferrin receptor or ferritin alone in particular when assessing iron status in 
pregnant women.  Total body iron should be used to assess maternal iron status when 
prescribing iron to pregnant women.  More research needs to be done to investigate 
maternal factors that affect iron status and their affect on infant total body iron.  
Suggestions for further research include a study specifically designed to answer the 
research question.  Having equal groups of iron deficient and iron replete subjects 
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would better assess factors that may affect iron status.  Another suggestion for 
research would be to assess dietary intake of iron through dietary recalls throughout 
the study. 
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Chapter 6 
SUMMARY 
 Total body iron is a sensitive indicator of iron status in pregnant women and 
infants and should be used in preference to hemoglobin and hematocrit.  Research has 
shown many factors affect maternal iron status.  However the fetus receives iron 
preferentially (1). 
 The observational investigation demonstrated that maternal and infant iron 
status can be correlated with infant gender and high blood pressure during pregnancy 
(p<0.05).  Women were followed between 8 and 20 weeks of gestation until the infant 
was four months of age.  During this time information was collected from subjects 
including known risk factors that affect iron status.  Medical records were also 
monitored.  It was expected that parity, smoking during or before pregnancy, alcohol 
consumption, BMI, preeclampsia, gestational diabetes, ethnicity, hemoglobin, birth 
weight, and gestational age at delivery would be correlated with maternal and infant 
total body iron.  These factors were most likely not correlated with maternal or infant 
body iron in this investigation because the study was not designed or powered to 
investigate total body iron. 
 Most of the current body of literature does not measure total body iron to 
assess iron status.  More research needs to be conducted concerning total body iron 
and factors that affect maternal iron status.  This study provides analysis to support 
that further investigation needs to be done to assess factors that affect maternal and 
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infant iron status using total body iron.  Parity, smoking during or before pregnancy, 
alcohol consumption, BMI, preeclampsia, high blood pressure, gestational diabetes, 
ethnicity, hemoglobin, birth weight, or gestational age at delivery may be used in the 
future as screening tools to further investigate maternal iron status.  Since total body 
iron is a more sensitive iron indicator, it should be used to assess iron status before 
iron supplementation is recommended.
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CONSENT FORM FOR PARTICIPATION IN A RESEARCH STUDY 
 
 The Effects of DHA on Pregnancy and Infant Outcome 
(Kansas University DHA Outcomes Study or KUDOS) 
 
Sponsor:  NIH (1R01 HD047315) 
 
 
INTRODUCTION  
As a pregnant woman who is between 8 and 20 weeks of gestation, you are 
being invited to enroll in a research study of a nutrient (DHA) that is a 
component of normal brain and important for brain development. The centers 
involved in the study are the University of Kansas Medical Center in Kansas City, 
Kansas, Truman Medical Center in Kansas City, Missouri and St. Luke’s Hospital in 
Kansas City, Missouri.  If you decide to enroll in this study, your baby will 
participate in research procedures at the University of Kansas Medical Center. Dr. 
Susan Carlson is the main investigator for this study.  A total of 350 pregnant 
women will be enrolled in this study between October 2005 and January 2010.  
 
You do not have to participate in this research study. It is important that before 
you make a decision to participate, you read the rest of this form. You should ask 
as many questions as you need to understand what will happen if you participate 
in the study. 
 
BACKGROUND  
Docosahexaenoic acid (DHA) is a fat that is found in very large amounts in the 
brain. DHA is important for how my baby sees and learns. Breast milk and, since 
2002, US formulas contain DHA.  Many studies have shown that DHA in the diet 
helps the baby’s vision, attention, and ability to learn.  In this way, DHA is 
considered an important nutrient for babies after they are born. 
 
DHA may also be important before babies are born. Four studies found that 
women’s DHA during pregnancy was related to higher infant/child function. 
These studies are called observational studies, meaning that the women’s normal 
DHA status was studied in relation to development of the baby/child. There is 
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only one study that gave women DHA during pregnancy and measured 
development of their babies/children. That study showed higher IQ at 4 years of 
age in children whose mothers took fish oil capsules during the last 6 months of 
pregnancy. (Fish oil contains a lot of DHA). However, because women in the study 
also consumed DHA while they were breastfeeding they provided more DHA to 
their babies after they were born. Therefore, the study does not prove that giving 
DHA before babies are born will help their development. There are no studies that 
have varied DHA intake only during pregnancy.  You and your child are being 
asked to participate in such an experimental study. 
 
PURPOSE 
The purpose of this study is to determine if a dietary supplement of DHA during 
pregnancy will help babies be born at the right time and help their development. 
If you decide to be in the study, you will have a 50-50 chance of receiving capsules 
with the supplement of DHA or ordinary food oil, which does not contain any 
DHA. 
PROCEDURES 
If you choose to enroll yourself and your infant in this study, the investigators will 
record some information from your medical record about your pregnancy and 
medical history. They will also ask you a few questions about foods that you 
usually eat.  You will have a blood sample collected from a vein in your arm.  
One-half teaspoon of blood will be drawn. The blood will be used to measure 
DHA in your blood as well as other nutrients.  You will be asked to provide a 
current address and phone number where you can be contacted.   
 
During pregnancy:  You will be randomly assigned (like flipping a coin) to 
capsules with DHA-oil or ordinary food oil (which does not contain any DHA). The 
DHA-oil is the same oil that is used in US infant formulas and has been fed safely 
to millions of infants.  
 
You will be given enough capsules each month to take 3 capsules each day and 
you agree to try to consume all 3 capsules. If you consume all 3 capsules, you will 
consume 600 mg of DHA. The capsules are relatively small and you should find 
them easier to swallow than many nutrient supplements. They are orange-
flavored, so if you burp (common in pregnancy and in the first week of taking any 
nutrient supplement), the taste should not be unpleasant. You do not need to 
take the capsules at any specific time as they are a nutrient and not a drug. 
However, you should decide upon a regular time to take them so that taking the 
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capsules will become a habit and you won’t forget. For example, you might wish 
to take them just before you go to bed or when you have your first beverage of 
the day.  
 
Neither you nor the investigators will know which capsules you have been 
assigned to. On the day you enroll for the study, we will send you home with 
your first bottle of capsules. About 30 days later (early enough so that you do not 
run out of capsule), you will receive another bottle of capsules in the mail. AT 
THAT TIME, YOU AGREE TO PLACE THE FIRST BOTTLE WITH ANY REMAINING 
CAPSULES IN THE ENVELOPE AND DROP IT INTO THE MAIL.   
 
This process will be repeated each month until your baby is born and you will 
continue to take 3 capsules per day until your baby is born. Each time you receive 
a new bottle, you will mail back the bottle that you have been using and that day 
will open and begin using the new bottle.  
 
The investigators will contact you by phone at least once per month. They will 
ask about capsule intake and they will ask how you are doing. Maintaining 
contact with our study personnel on a monthly basis is very important. 
 
IF YOUR PHONE NUMBER OR ADDRESS CHANGES AT ANY TIME DURING THE 
STUDY, YOU WILL LET THE INVESTIGATORS KNOW BY CALLING 913-588-3781 
AND LEAVING A MESSAGE.  
 
Delivery:  After you are admitted to the hospital to deliver, you should telephone 
study personnel or ask the person at admitting to telephone them. You will be 
given a cell phone number today to call.  Once you deliver your baby, the 
investigators will visit you in the hospital to collect data about your delivery and 
your baby’s health.  A sample of your baby’s cord blood will be collected after 
delivery by nurses at the hospital and given to the investigators.  A nurse will also 
draw a small blood sample (one-half teaspoon) from you while you are in the 
hospital. The blood samples will be used to measure DHA and other nutrients. 
The investigators will visit you, and give you an appointment for your baby’s first 
follow-up visit at KUMC. 
 
Visit 1 (6 weeks of age):  The investigators will measure how your baby sees 
using a test that involves placing 3 electrodes directly on your baby’s head. The 
process involves cleaning the area then placing a small amount of paste similar to 
toothpaste on the head. The electrodes are placed on top of the paste. The 
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electrodes will be used to record your baby’s brain waves while he/she is looking 
at pictures. Your child’s weight, height and head circumference will be measured 
again and you will be asked questions about what your baby eats.  If you are 
breastfeeding your baby, you will be asked to provide a teaspoon of breast milk 
to the investigator. The sample will be frozen and analyzed for fats that are 
found in the capsules. The visit should last about 40 minutes. You should arrive 
on time and allow that amount of time for the visit. 
 
Visit 2 (4 months of age): The investigators will measure how your baby sees 
using the same test as before and another vision test. Your baby will wear a pair 
of plastic glasses during the second test. In another test, your child will be given 
an object to look at several times.  The investigator will measure how long 
he/she looks at the object and how quickly he/she stops looking at the object. 
Your child will be video recorded during the test. Your baby’s heart rate will be 
measured during the test.  Your baby’s height, weight and head circumference 
will be measured and you will be asked about what food your baby eats. Your 
baby will have a blood sample collected by either heel stick or drawn from a vein.  
If it is necessary to use a heel stick, the investigator may use a cream or spray 
that will numb the area before obtaining the sample.  One-half teaspoon of 
blood will be drawn. The blood will be used to measure DHA and other nutrients. 
You should let the investigator know if your baby has been sick or not acting well 
since his/her last visit.  The visit will take 60-90 minutes.  
 
Visit 3 (6 months of age): The investigators will measure how your baby sees 
using the test that requires him/her to wear a pair of plastic glasses. In another 
test, he/she will be given an object to look at several times (just like at 4 months 
of age).  The investigator will measure how long he/she looks at the object and 
how quickly he/she stops looking at the object. Your child will be video recorded 
during the test. Your baby’s heart rate will be measured during the test.  Your 
baby’s height, weight and head circumference will be measured.   You will be 
asked questions about what your baby eats.  You should let the investigator 
know if your baby has been sick or not acting well since his/her last visit.  The 
visit should take 40 -60 minutes.  
 
Visit 4 (9 months of age):  Your baby will have both tests that measure how 
he/she sees. In another test, your child will be given an object to look at several 
times (just like at 4 and 6 months of age).  The investigator will measure how 
long he/she looks at the object and how quickly he/she stops looking at the 
object and your baby’s heart rate will be measured during the test. Your child will 
be video recorded during the test. Your baby’s height, weight and head 
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circumference will be measured. You will be asked questions about what your 
baby eats.  You should let the investigator know if your baby has been sick or not 
acting well since his/her last visit. The visit should take about 40-60 minutes.  
 
Visit 5 (10 months of age):  During this visit your baby will be placed on your lap 
in front of a small table.  A test will be completed with a small toy, foam block 
and 2 cloths that will be placed in front of your child. You will also take a short 
language test. The small toy will be given to your child to keep. In another test, 
your baby will be asked to take turns with the researcher building fun toys. After 
your baby has played for a moment with the pieces, the researcher will show him 
or her how to build the toy. Then, your baby will be given a turn to put the toy 
together. Your baby’s turn will happen either immediately or after 10-minutes of 
play with other things.  Your child will be video recorded during the tests.  You 
should let the investigator know if your baby has been sick or not acting well 
since his/her last visit.  You will be asked questions about what your baby eats. 
The entire 10-month visit should last 65 - 70 minutes.  
 
Visit 6 (12 months of age):  The investigators will measure how your baby sees 
using both vision tests. Your child will be video recorded while playing with an 
interesting toy and the investigator will use the recording to measure some 
aspects of attention.   Your child’s height, weight and head circumference will be 
measured.   You will be asked questions about what your baby eats.  You should 
let the investigator know if your child has been sick or not acting well since 
his/her last visit.  The visit should take about 2 hours.  It is important that your 
child be rested before the testing at this visit. If for some reason your baby 
cannot finish the tests that day – this may happen if he/she is unusually fussy or 
tired – you will be asked to return to finish the remaining tests within 7 days.  
 
Visit 7 (18 months of age):  The investigators will measure how your child sees 
using the test that he/she had while wearing plastic glasses.  Your child will be 
video recorded while playing with an interesting toy and the investigator will use 
the recording to measure some aspects of attention. Your child will also be given 
a standardized test to measure mental and physical development. Your child’s 
height, weight and head circumference will be measured. You will be asked 
questions about what your baby eats.  You will be asked questions about the 
words your child uses and understands.   You should let the investigator know if 
your child has been sick or not acting well since his/her last visit.  The visit should 
take about 2 hours.  It is important that your child be rested before the testing at 
this visit. If for some reason your child cannot finish the tests that day – this may 
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happen if he/she is unusually fussy or tired – you will be asked to return to finish 
the remaining tests within 7 days.  
 
RISKS 
Some redness, soreness, or bruising may occur at the site of blood sampling.  
There is also a very slight risk of infection.  
 
You may experience burping from the capsules and find this unpleasant 
 
There are no known risks of consuming the amount of DHA you will be provided 
if you receive the DHA. Even if you forget to take your capsules for one or two 
days, there is no known risk of deciding to “catch up” on the third day. The 
amount is smaller than pregnant women in many countries eat every day. 
Nevertheless, you could develop a problem that has not been observed before. 
 
NEW FINDINGS STATEMENT 
You will be informed if any significant new findings develop during the course of 
the study that may affect your willingness to participate or to allow your child to 
participate in this study. 
 
BENEFITS 
You and your child may or may not benefit from participating in this study. If you 
receive the supplement, it may help your baby to be born at the right time and 
your baby’s/child’s development. If you will not get the supplement, your baby 
and you will not be getting any of those benefits. It is also possible that all 
infants/children will get some benefit from being followed closely with 
developmental testing. It is hoped that additional information gained in this 
research study may be useful in understanding if DHA can help your baby be 
born at the right time and help your baby’s vision, attention, and learning as he 
or she grows. You will receive a video recording of your infant doing the 4, 6, and 
9 month looking test when the 12 month visit is complete. 
 
ALTERNATIVES 
You do not have to participate in this study to be able to take DHA supplements 
while you are pregnant. You may purchase capsules containing DHA at local 
stores without a prescription (for example, Osco, Costco, Wal-Mart). There are 
also several brands of prenatal supplements with DHA available by prescription 
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or over the counter.  The prenatal capsules typically contain 200 mg of DHA each 
and are marketed to take one capsule/day as a DHA supplement.  
 
COSTS 
Capsules containing either DHA or food oil will be provided to you at no cost 
while you are participating in this study.  You will not incur any costs because of 
your or your child’s participation  
 
PAYMENT TO SUBJECTS 
If study investigators are able to communicate with you each month you will be 
given 2 bonus gift cards to either Wal-Mart or Target of $25 each. The first gift 
card will be given to you half way through your treatment phase if 
communication is maintained at least one time each month during the first half 
of your treatment. The second gift card will be given at delivery if communication 
maintained at least one time each month during the second half of your 
treatment.  
 
Additionally, if the study investigators are called after you are admitted for 
delivery you will be given your choice of a bonus gift card worth $50 from either 
Wal-Mart or Target. You may make the call yourself or have someone else call for 
you. Study personnel will give you the gift card when they come to the hospital 
after your baby is born.   
 
Once your baby is born, you will receive a check for $50 after your baby 
completes each of the following visits: 6 weeks, 4 months, 6 months, 9 months, 
and 10 months. You will receive a check for $100 after your child completes each 
of the following visits: 12 and 18 months. The reimbursements are to cover the 
costs of transportation and to partially compensate you for your time required to 
participate in the study.  
 
Your name, address, social security number, and the title of this study will be 
given to the KUMC Research Institute.  This is done so that the Research Institute 
can write a check for study payments.  Payments are taxable income. 
 
IN THE EVENT OF INJURY 
In the event you experience any serious health problem (hospitalization, life-
threatening illness, or death) for any reason during your pregnancy, you should 
immediately seek treatment or help in the way you normally would as if you 
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were not in a study. You should let Susan Carlson, Ph.D. know about any of these 
problems as soon as possible by calling her office (913-588-5359) or the study 
office (913-588-3781). A message may be left at both numbers.  Dr. Carlson may 
also be reached at home (816-960-1805). 
 
INSTITUTIONAL DISCLAIMER STATEMENT 
Although the University of Kansas Medical Center does not provide free medical 
treatment or other forms of compensation to persons injured as a result of 
participating in research, such compensation may be provided under the terms 
of the Kansas Tort Claims Act.  If you believe you or your child has been injured 
as a result of participating in research, you should contact the Office of Legal 
Counsel, University of Kansas Medical Center, Kansas City, KS 66160-7101. You 
do not give up any of your or your child’s rights by signing this form. 
  
Truman Medical Center (TMC) will provide medical attention to you if you suffer 
any injury or harm as a direct result of participating in this research project.  
TMC, your study doctor, and the sponsor of this study will decide, in their 
discretion, who should pay for the medical care.   TMC will provide treatment for 
you in the event of any medical emergency while present at TMC, whatever the 
cause.  Moreover, you will have the benefit of the coverage of any existing health 
insurance you own. Truman Medical Center shall not be required to bill third 
party payers for any expenses related to this research study. No other 
compensation of any type will be provided by TMC or the sponsor.  
 
Participation in this research study does not take the place of routine physical 
examinations or clinic visits to your personal physician.  If you believe you have 
been injured as a result of participating in this study you are encouraged to 
contact the study investigator, Dr. Susan Carlson, at her work number, 913-588-
5359. 
 
The University of Missouri-Kansas City appreciates the participation of people 
who help it carry out its function of developing knowledge through research. 
Although it is not the University’s policy to compensate or provide medical 
treatment for persons who participate in studies, if you think you have been 
injured as a result of participating in this study, please call the investigator, Dr. 
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Susan Carlson, at her work number, 913-588-5359. or the IRB Administrator of 
UMKC’s Adult Health Sciences Institutional Review Board at 816-235-6150.  
 
CONFIDENTIALITY AND PRIVACY AUTHORIZATION 
Names of subjects or information identifying subjects will not be released 
without written permission unless required by law.  Videotapes of your baby 
when he/she is looking at pictures and playing with toys will be used only by the 
investigators and their students and to make a videotape copy for you.  The 
videotapes will be secured under lock and key like all other information that 
could be linked directly to your child. The videotape of your child will not be 
shown without specific permission from you and even then would not identify 
your child by name.  Efforts will be made to keep you and your child’s personal 
information confidential.  Researchers cannot guarantee absolute confidentiality.  
If the results of this study are published or presented in public, information that 
identifies you and/or your baby will be removed.  
 
The privacy of you and your child’s health information is protected by a federal 
law known as the Health Insurance Portability and Accountability Act (HIPAA).  If 
you choose to participate in this study, you will be asked to give permission for 
researchers to use and disclose your and your baby’s health information that is 
relevant to the study.    
 
To perform this study, researchers will collect health information about me and 
my child from his/her and my medical records and from the study activities that 
are listed in the Procedures section of this consent form.  My and my baby’s 
study-related health information will be used at KU Medical Center by Dr. 
Carlson, members of the research team, Truman Medical Center, St. Luke’s 
Hospital andthe KU Hospital Medical Record Department. The KUMC Research 
Institute as well as officials at Truman Medical Center and St. Luke’s Hospital that 
oversee research, including the KUMC Human Subjects Committee, the IRB that 
governs Truman Medical Center and St. Luke’s Hospital and other committees 
and offices that review and monitor research studies, may also see my and my 
baby’s study-related health information 
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Dr. Carlson and her team may share information about me and my baby with 
representatives of Martek Biosciences, the monitoring company who verifies 
study data, the laboratory that processes study lab samples, other business 
partners who help with the study, the U.S. Food and Drug Administration (FDA), 
and U.S. agencies that govern human research (if and when regulatory 
compliance issues arise). Martek Biosciences (Columbia, MD) donated the 
capsules for this study that is otherwise supported by the National Institute of 
Child Health and Human Development.   
 
Some of the persons or groups that receive my and my baby’s study information 
may not be required to comply with HIPAA privacy laws.  My and my child’s 
information may lose its federal protection if those persons or groups disclose it.   
 
Permission granted on this date to use and disclose my health information 
remains in effect indefinitely.  By signing this form I give permission for the use 
and disclosure of my and my child’s information for purposes of the study at any 
time in the future. 
 
If I enroll in the study, the investigators cannot tell me what capsule I was 
assigned to until the study ends. This may be after I have stopped taking the 
capsules. 
 
QUESTIONS 
I have read the information in this form. Dr. Carlson or her associates have 
answered my question(s) to my satisfaction.  I know if I have any more questions 
after signing this I may contact Dr. Carlson or one of her associates at (913) 588-
5359.  If I have any questions about my or my child’s rights as a research subject, 
I may call (913) 588-1240 or write the Human Subjects Committee, University of 
Kansas Medical Center, 3901 Rainbow Blvd. MSN 1032, Kansas City, KS 66160. 
 
SUBJECT RIGHTS AND WITHDRAWAL FROM THE STUDY 
My and my child’s participation in this study is voluntary and the choice to not 
participate or to quit at any time can be made without penalty or loss of benefits.  
Not participating or quitting will have no effect upon the medical care of 
treatment my child receives now or in the future at the University of Kansas 
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Medical center.  The entire study may be discontinued for any reason without my 
consent by the investigator conducting the study, by the sponsor of the study, or 
the FDA.  My child’s participation can be discontinued by the investigator or by 
the sponsor if it is felt to be in my child’s best interest or if I do not follow the 
study requirements.  If I choose to withdraw before my child is 18 months of age, 
I may be asked to answer questions about the study on the telephone. 
 
If I want to cancel permission to use my or my child’s health information, I should 
send a written request to Dr. Carlson.  The mailing address is Susan Carlson, 
Ph.D., Dept. of Dietetics and Nutrition, MS 4013, 4019 Delp, University of Kansas 
Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160. If I cancel 
permission to use my child’s health information, the research team will stop 
collecting any additional information about me and my child. 
 
Should the study be terminated prior to the completion of my pregnancy, neither 
the investigator nor the University of Kansas Medical Center will be under any 
obligation to provide me with DHA capsules used in the study.  
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CONSENT 
Dr. Carlson or her associates have given me information about this research 
study.   
They have explained what will be done and how long it will take.  They explained 
the inconvenience, discomfort and risks that may be experienced during this 
study.   
 
By signing this form, I give my permission for my and my child’s health 
information to be used and disclosed for the purposes of this research study.  If I 
choose not to sign this form, my child and I will not be able to participate in the 
study.   
  
I voluntarily consent to my and my child’s participation in this research study.  I 
have read the information in this form and have had an opportunity to ask 
questions and have them answered.  I will be given a copy of the signed form to 
keep for my records. 
____________________________________    
Type/Print Subject's Name       
 
____________________________________ _________________________ 
Signature of Subject       Time   Date 
 
____________________________________ 
Type/Print Name of Person Obtaining Consent 
 
____________________________________  __________________ 
Signature of Person Obtaining Consent     Date 
 
____________________________________ 
Type/Print Name of Principal Investigator 
 
____________________________________  __________________ 
Signature of Principle Investigator      Date 
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May the investigators contact you after the study is over to ask if you interested 
in continuing your child’s participation?  If you agree to be contacted, the 
investigators would explain any new study to you later and you would have the 
chance to decide if you wanted to participate at that time (please circle your 
response). 
 
Yes 
 
No  
 
____________________________________    
Type/Print Subject's Name       
 
 
____________________________________ _________________________ 
Signature of Subject       Time   Date 
 
 
____________________________________ 
Type/Print Name of Person Obtaining Consent 
 
____________________________________  __________________ 
Signature of Person Obtaining Consent     Date 
 
 
____________________________________ 
Type/Print Name of Principal Investigator 
 
 
____________________________________  __________________ 
Signature of Principle Investigator      Date
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Procedure taken from insert of Enzyme Immunoassay for quantifying Human Transferrin 
Receptors in Serum or Plasma (Catalog #TFR-94) 
 
Ramco Laboratories, Inc 
4507 Mt. Vernon 
Houston, TX 77006 
 
1. Remove plasma samples from -80ºC freezer and allow to thaw 
2. Remove the necessary strips from the packet and place in Microwell Frame (any unused 
strips must be returned to and resealed in the ziplock foil packet, returned to 2-8ºC and 
used in 6 weeks) 
3. Prepare a 1:100 dilution of each patient sample and Control by dispensing 1ml of 
Sample Dilutent into a test tube and adding 10μl of patient serum or plasma or Control.  
Mix thoroughly.  DO NOT dilute standards 
4. Pipette 50μl of each diluted patient sample and control, in duplicate, into individual 
wells 
5. Pipette 150μl of HRP-conjugate into all individual wells containing samples, controls, 
and standards 
6. Seal the microwell strips with the self-adhesive plastic film and place on a rotating table 
and mix for 10 minutes at 190nm or rotate by hand, pressing the frame firmly against 
the counter to avoid sloshing, to ensure mixing of the HRP-conjugate with the samples, 
controls, and standards.  Allow reaction to proceed for an additional 2 hours (no 
rotation) at room temperature upon completion of mixing 
7. Prepare the substrate solution: calculate the amount of substrate solution needed by 
multiplying 0.2ml by the number of wells in the assay run plus 0.5-1ml dead volume.  
Mix equal volumes of TMB substrate solution A and TMB substrate solution B just prior 
to addition of the microwells.  This should be used within 30 minutes of preparation. 
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8. After the 2 hours incubation, remove plastic film, invert the plate, and dump the 
contents of the microwell strips.  Tap the plate dry on absorbent pad or paper towels.  
Wash the wells with the prepared washing solution (wash solution 5X in 250ml 
graduated cylinder QS to 250ml) using a plate washing device or by using the wash 
bottle to flood the wells and then invert and dump the contents of the wells.  The wells 
should be washed a total of 3 times, tapping dry between each wash.  After the final 
wash, make sure the wells are completely empty 
9. Pipette 200μl of substrate solution into each well containing samples, controls, and 
standards, and incubate in the dark at room temperature for 30 minutes.  A blue color 
should develop in those wells containing TfR 
10. Stop the color reaction by pipetting 50μl of acid stop solution into the wells and mix 
briefly to remove any air bobbles 
11. Read the absorbance of each well at 450nm using a microplate reader.  It is 
recommended that the reader be zeroed using blanks prepared with 200μl of substrate 
solution and 50μl acid stop solution 
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FER-IRON II  
An Immunoradiometric Procedure  
For The Quantitative Analysis of Serum Ferritin.  
Catalog Number: T-13  
SUMMARY  
The serum ferritin concentration is proportional to the amount of iron in stores in the human 
body. The measurement of serum ferritin enables the clinician to differentiate between the 
anemia caused by iron deficiency and other forms of anemia
1,2,3
. Serum ferritin concentration 
is a useful, noninvasive screening test for iron overload, which may allow the detection of 
idiopathic hemochromatosis in the precirrhotic stages
4
.  
TEST PRINCIPLE  
This is a one stage, 2-site immunoradiometric (sandwich) assay. Antibody to ferritin is coated 
on the surface of the plastic beads. Ferritin present in sera or calibrators binds to the antibody 
coated beads. Radiolabeled antibody in turn binds to the ferritin on the solid phase antibody 
(forming a "sandwich"). The solid phase is washed and counted in a gamma counter. The 
amount of radiolabel bound to the solid phase is directly proportional to the concentration of 
ferritin present in the sera or calibrator solutions.  
   
REAGENTS  
Prediluted Ferritin Calibrator Solutions:    6 vials containing 0.3ml of human spleen ferritin 
diluted to concentrations of 6, 20, 60, 200, 600, and 2000 ng/ml in borate buffer containing 
bovine serum albumin, rabbit serum, sodium chloride, and inert coloring agents with sodium 
azide as a preservative.  Store at 2 - 8C.   Do Not Use After Expiration Date.  
Note: The ferritin concentration of the base stock of cadmium crystallized human spleen 
ferritin from which these calibrators were derived was established by a protein determination. 
As such, these calibrators have more immunologic reactivity than WHO calibrators. Values 
for the Control Sera and for the Patient Samples will be approximately 25.4% lower than 
those observed using WHO calibrators.  
Solid Phase Antihuman Ferritin:   128 plastic beads (Beads) coated with rabbit antihuman 
spleen ferritin and stored in a bottle containing borate buffer with bovine serum albumin, 
rabbit serum, and sodium chloride with sodium azide as a preservative.   Store at 2 - 8C.   Do 
Not Use After Expiration Date.  
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Sample Diluting Buffer (Blue Solution):   1 bottle containing 30 ml of borate buffer with bovine 
serum albumin, rabbit serum, sodium chloride, ethylenediaminetetra-acetate, and inert 
coloring agents with sodium azide as a preservative.   Store at 2 - 8C.   Do Not Use After 
Expiration Date on Bottle.  
Radiolabeled (
125
I) Antihuman Ferritin (Red Solution):   1 bottle containing 27 ml of 
radiolabeled (
125
I) rabbit antihuman spleen ferritin dissolved in borate buffer with bovine 
serum albumin, rabbit serum, sodium chloride, ethylenediaminetetra-acetate, inert coloring 
agents and sodium azide as a preservative. This kit contains less than 10 uCi (370 kBq) of 
radioactivity.   Store at 2 - 8C.   Do Not Use After Expiration Date on Bottle.:    
Reaction Trays and Grippers:    4 Reaction Trays containing 32 Reaction Wells each plus 128 
bead Grippers.  
Graph Paper:    3 sheets of Standard Plot logit-log graph paper.  
PRECAUTIONS  
This Kit is Intended for In-vitro Diagnostic Use Only  
WARNING - RADIOACTIVE MATERIAL  
1. Do not pipette radioactive material by mouth.  
2. Use only in a designated area.  
3. Store in the original container in a designated area.  
4. Clean up spills with paper towels and dispose of in accordance with approved regulations.  
5. Used radioactive solutions and solids should be disposed in accordance with approved 
regulations (see 10 CRF part 20).  
WARNING -   The human ferritin in the calibrator solutions has been tested and found to be 
nonreactive for Hepatitis B Antigen by RIA, and antibody to HTLV III by ELISA. The calibrator 
solutions as well as the patient specimens and control sera should be considered potentially 
hazardous and handled in accordance with approved laboratory procedures and regulations.  
WARNING -  Reagents in this kit contain sodium azide. Contact with copper or lead drain 
pipes may result in the formation of explosive azide deposits. It is important during disposal to 
flush drains with copious amounts of water to prevent azide accumulation. Plumbing that may 
be contaminated with azides can be flushed with 10 percent sodium hydroxide solution.  
Other Precautions:  
 Avoid splashing or generating aerosols.  
 Follow kit recommendations for incubation times and temperatures to avoid 
possibly erroneous results.  
 Microbial contamination of reagents may cause erroneous results.  
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 Do not use reagents with those from other lots or manufacturers.  
 Do not use kit reagents after the expiration date.  
SAMPLE COLLECTION AND PRESERVATION  
Collect 5 ml of venous blood aseptically. Allow the blood to coagulate and separate the 
serum from the clot by centrifugation. Plasma may also be used for ferritin analysis. Moderate 
hemolysis will not interfere with the assay. If the assay will be performed within 7 days, store 
the serum refrigerated. If more than 7 days will elapse before the test is performed, the serum 
specimen should be frozen. Serum specimens may be stored frozen for 4 months without 
change in the ferritin content.  
    
MATERIALS REQUIRED BUT NOT PROVIDED  
 Deionized or distilled water.  
 Precision pipettes capable of delivering volummes of 10 and 200 ul.  
 12 X 75 mm glass or plastic test tubes.  
 Gamma counter capable of detecting 
125
I.  
 Clinical rotator table or vibrator table  
GENERAL INFORMATION ON PROCEDURE  
Serum ferritin levels up to 2000 ng/ml may be measured without prediluting serum 
specimens. If precision is required for higher concentrations, samples may be diluted with 
sample diluting buffer and reassayed. Precision techniques are necessary for accurate and 
reproducible results. All solutions should be dispensed directly into the bottom of the reaction 
tube.  
ASSAY PROCEDURE  
Determine the number of Solid Phase Antihuman Ferritin Beads needed for the assay and 
label the Reaction Trays and Grippers accordingly. Allow reagents, sera, and patient samples 
to reach room temperature before performing the assay.  
1.   Beginning with Reaction Well A3 (skip Wells A1 and A2), pipette 10 ul of Prediluted 
Ferritin Calibrator Solution and sample, in duplicate, into separate Wells. Reaction Wells A1 
and A2 measure non specific binding and only contain the Radiolabeled Antihuman Ferritin 
and Antihuman Ferritin Coated Beads.  
2.   Pipette 200 ul of Radiolabeled Antihuman Ferritin (red solution) into each Well and place 
the tray(s) on a clinical rotator table for 5 minutes at 200 rpm to assure mixing.  
3.   Add 1 Bead to each Reaction Well and place the numbered Grippers into the Reaction 
Wells. Push down firmly to attach the beads.  
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4.   Incubate on a clinical rotator (200 rpm) or vibrator table for 2 hours at room temperature. 
(For those requiring a more rapid assay the incubation time can be reduced to 1 hour at room 
temperature.)  
5.   Wash Beads under running deionized water while still attached to Grippers. Shake to 
remove excess water.  
6.   Remove each Bead or Bead plus Gripper to a counting tube.  
7.   Count in a gamma counter for 1 minute.  
8.   Calculate results. (See CALCULATION section below.)  
NOTE:  A rotating table or vibrator table must be used for a 1 or 2 hour incubation period. 
Extend the incubation period to overnight (14-18 hours) at room temperature if a mixing 
device is not used. Steps 1 through 8 are otherwise unaltered.  
SUMMARY OF ASSAY PROCEDURE  
Procedure Flow Sheet:  
   
Reaction Well              Calibrator  (ul)     Patient Sera (ul)    Radiolabeled  Antibody (ul)      Incubation  
A1 & A2                             **(0 ng)              --                               200  
A3 & A4                       10     (6 ng)              --                               200                       INCUBATE FOR  
A5 & A6                       10    (20 ng)             --                               200                        2 HOURS ON A  
A7 & A8                       10    (60 ng)             --                               200                           SHAKING OR  
A9 & A10                     10   (200 ng)             --                               200                            VIBRATING  
A11 & A12                   10   (600 ng)             --                               200                                TABLE  
B1 & B2                       10  (2000 ng)            --                               200  
B3 & B4                        --                           10                               200  
etc                                --                           10                               200  
   
**The 0 ng/ml calibrator consists of the 200 ul radiolabeled antiferritin only and is used to measure nonspecific binding 
 (NSB).     
After the incubation period, wash each Bead under running deionized water, and shake to 
remove excess fluid.  
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Count Beads in gamma counter for 1 minute.  
 
CALCULATIONS  
Calculate the mean total count for each calibrator and patient serum. Determine the net count 
by subtracting the mean count of the 0 calibrator (NSB) from each.  
   
I.   ESTIMATION OF MAXIMUM BINDING (MB)  
Maximum Binding (MB) now must be determined. Either of the following techniques are 
satisfactory:  
 METHOD I:     Maximum Binding (MB) can be estimated using the formula:  
                     MB = C2(2C1C3 - C1C2 -C2C3) /[(C1C3) -(C2)
2
]  
               Where:    C1 = net counts of 20 ng calibrators  
C2 = net counts of 200 ng calibrators  
C3 = net counts of 2000 ng calibrators  
              Example using Example Data Table:  
                    MB = [30493 (2(3736 × 76797)-(3736 × 30493)-(30493 × 76797))] / [(3736 × 
76797) -(30493)
2
]  
                    MB = -5.738374 × 10
13 
/ -6.429095 × 10
8
 = 89256  
METHOD II:   The net counts of the 2000 ng/ml calibrator multiplied by the factor on the 
quality control sheet enclosed in the kit closely approximates MB.  
Example:    76797 × 1.15 = 88317  
II.   CALCULATION OF PERCENT BOUND (PB)  
Once (MB) has been derived, the Percent Bound (PB) must be determined for each calibrator 
and unknown.  
PB = 100 x Net counts for each cal. or unknown / MB  
Example for Normal Serum from Example Data Table:  
PB = 100 x 19685/89256 = 22%  
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III.   CONSTRUCTION OF THE CALIBRATION CURVE  
Construct a best fit line on the Logit-Log paper supplied with the kit, plotting the Percent 
Bound of each calibrator versus its ferritin concentration in ng/ml. Read the concentration of 
each unknown directly from the graph of the calibrator response curve.  
IV.   OTHER METHODS OF DATA REDUCTION  
Other methods of data reduction may be used to analyze the 2-site IRMA assay of ferritin. 
These include the plots of:  
1. Counts bound (B) versus the log of the ferritin concentration.  
2. Counts per minute versus ferritin concentration on a semi-log graph. It has been 
demonstrated that the data conforms closely to a Scatchard plot.  
3. Percent Bound:  
Bound / Total × 100 versus the log of the ferritin concentration  
4. Automated Methods: Available on most multi-sample gamma counters. Refer to the 
instrument's operating manual for details.  
Alternatively, the serum concentration of ferritin can be calculated from a regression 
equation. If you desire to use this form of calculation, call Ramco Laboratories at 800-231-
6238 or 281-313-1250.  
   
EXAMPLE DATA  
(For Demonstration Purposes Only)  
COUNT TIME = 1 MINUTE  
   
                    TOTAL                                                                                           CONC.  
ng/ml          COUNTS                MEAN               -NSB**                PB*                  ng/ml  
                        275                                                                                                                 0 or 
NSB*         293                      284  
                      1390                                                                                                               
6                    1211                     1301                  1017                 1.1  (1.2)  
                      3958                                                                                                              
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20                  4082                     4020                  3736                 4.2  (4.2)  
                    11015                                                                                                              
60                  9950                   10483                 10199               11.4  (11.5)  
                    29064                                                                                                            
200               32489                   30777                 30493               34.1  (34.5)  
                    54018                                                                                                            
600               53946                   53982                 53689               60.1  (60.8)  
                    78000                                                                                                          
2000             76161                   77081                 76797                86.0  (87.0)  
Normal          19875                                                                                                       
Serum           20063                  19969                  19685                22.0  (22.3)         112  (114)  
Iron Deficient   2482                                                                                                        
Serum            2484                    2483                    2199                   2.5  (2.5)            12  (12)  
   
ESTIMATED MAXIMUM BINDING (MB) = 89256 (88317)  
*PERCENT BOUND (PB) was estimated using Method I calculation for MB, the results in parenthesis were estimated using 
Method II calculation for MB.  
**0 ng/ml calibrator measures nonspecific binding (NSB).  
Concentrations for normal and iron deficient serum were determined using the Example data Logit-Log Graph.  
LIMITATIONS OF THE PROCEDURE  
Moderate hemolysis has no effect upon the reproducibility or accuracy of the procedure. No 
drugs or other administered substances have been found to produce any effect on tests. 
Anticoagulants have not been shown to influence the test so long as they do not result in 
dilution of the plasma. Strict adherence to precise laboratory procedure is essential for 
maximum accuracy of the final results.  
EXPECTED VALUES  
Normal values are age and sex dependent. Serum ferritin concentrations greater than 300 
ng/ml may indicate increased iron stores as seen in idiopathic hemochromatosis.  
The serum ferritin concentration reflects the amount of iron in stores. In iron deficiency, the 
stores are gone and the serum ferritin is very low (less than 20 ng/ml). In other kinds of 
anemia iron stores are higher than normal and the serum ferritin values are usually over 100 
ng/ml. Values between 20 and 100 ng/ml in anemic patients may suggest a combination of 
iron deficiency with some cause of anemia. Serum ferritin concentrations greater than 300 
ng/ml are elevated and may indicate increased iron stores as seen in idiopathic 
hemochromatosis.  
 
59 
 
   
PERFORMANCE CHARACTERISTICS  
Intra-Assay Precision:  
                          NUMBER OF                     MEAN                                                     
SAMPLE              SAMPLES                        ng/ml            +/- 1 SD                C.V.  
       1                         8                                 18.1                0.23                   1.2%  
       2                         8                                 62.9                1.19                   1.9%  
       3                         8                               228.0                7.48                   3.3%  
Inter-Assay Precision:  
   
                       NUMBER OF                     MEAN                                      SAMPLE           
SAMPLES                        ng/ml             +/- 1 SD                  C.V.  
      1                     12                                 10.6                 0.69                     6.5%  
      2                     12                                 54.2                 3.19                     5.9%  
      3                     12                                202.0              13.20                      6.5%  
   
   
SENSITIVITY  
Sensitivity is defined as the smallest value of ferritin which can be distinguished from the zero 
standard with a 95% confidence limit (+/- two standard deviations). Using the 10 ul sample 
size specified in the assay procedures, the smallest concentration of ferritin that can be 
distinguished from zero is 0.23 ng/ml.  
 This Kit Contains Ramco Calibrators  
The concentrations of the Ramco Calibrators contained in this kit was established by a 
protein determination of the base stock of cadmium crystallized human spleen ferritin. As 
such, these Calibrators have more immunologic reactivity than WHO calibrators. Values for 
the Control Sera and for the Patient Samples will be 13.0% lower than those observed using 
WHO Calibrators (3rd International Standards for Ferritin, Recombinant NIBSC code: 94/572; 
National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters 
Bar, Hertfordshire, EN6 3QG, UK).  
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To convert the values for the Control Sera and Patient Samples to equivalent WHO values, 
multiply the values obtained using these Ramco Calibrators by 1.34.  
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CASE REPORT FORMS  
 
FOR PREGNANCY PORTION OF STUDY 
 
 
 
 
 
PATIENT INVESTIGATIONAL NUMBER: _____________ 
 
 
PATIENT INITIALS: _____________ 
 
 
DATE OF PATIENT CONSENT: __________________ 
       (MMM/DD/YYYY) 
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INCLUSION / EXCLUSION CRITERIA 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
Inclusion: 
 Pregnant female age 16 – 35.99 yrs:    yes   no   
 
 Gestation between 8 and 20 weeks:    yes   no  
   
 Signed Informed Consent     yes   no 
  
Date: _________ (mmm/dd/yyyy) 
 
Time: _________ (24 hour clock hh:mm) 
  
BMI <40        yes   no 
  
 Willing to consume 3 small capsules/day    yes   no 
 
 English speaking       yes   no 
   
Exclusion: 
 
Pre-existing diabetes mellitus (Type I, II  
or GDM)         yes   no 
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MEDICAL HISTORY 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
  
 
 
 
 
Blood Pressure at Enrollment: _______/________ 
        Systolic /  Diastolic 
 
 YES NO If Yes Please Specify 
 
Reproductive History 
 
 
XX 
 
XX 
 
Gravida ___ Para __ __ __ __ 
 T PT A L 
Smoking  
Before Pregnancy 
  PPD________ Years _______ 
 
Pack Years _______ 
(# of PPD X Years Smoked) 
 
Smoking During Pregnancy 
 
  # of cigarettes per day: _____ 
 
If was a smoker, date 
stopped: ____/____/____ 
                     mmm/dd/yyyy 
 
Alcohol Intake Before 
Pregnancy 
 
   
Amount per day: __________ 
(# of standard drinks/day – drinks/day 
from source and amount of alcohol)) 
 
Alcohol Intake  
During Pregnancy 
 
   
Amount per day: __________ 
 (# of standard drinks/day – drinks/day 
from source and amount of alcohol) 
 
Mother’s Date of Birth 
 
 
XX 
 
XX 
 
____/____/____ 
  mmm/dd/yyyy 
Other relevant history:                                      Current Medications: 
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PHYSICAL EXAMINATION 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
 
 
 
 
 
Maternal Height  
Inches     
Maternal Weight at Enrollment  
_______ Pounds     Pre-pregnancy Wt______ 
Body Mass Index at Enrollment  
BMI 
Last Menstrual Period 
 
_____/_____/______     [    ] Unknown 
        mmm/dd/yyyy 
 
 
EDD based on LMP: _____/______/_______ 
Ultrasound on _____/____/____ 
                                                    mmm/dd/yyyy 
 
Approximate Gestational Age: __________ 
 
 
EDD based on U/S: _____/______/_______ 
FINAL Expected Date of Delivery  
Notes: 
 
 
 
 
 
 
 
  
_____/_____/______ 
mmm/dd/yyyy 
Maternal years of education 
 
 
Average frequency of fish intake 
during pregnancy 
_________________________________ 
If yes, kind of fish eaten: _________________ 
Preterm Birth in previous pregnancy 
If yes, number of times and wks gestation: 
 yes   no  
____________________________________ 
Blood pressure ≥140/≥90 mm Hg 
during pregnancy? 
 
24-hour urine protein loss (if done) 
 yes   no  
 
 
_______________________________ 
Preeclampsia in current pregnancy 
 
Preeclampsia in previous pregnancy  
 yes   no 
 
 yes   no 
Gestational Diabetes in previous 
pregnancy. If yes, number of pregnancies: 
 yes   no  
______________________________________ 
One hour load glucose after 26-28 wk 
50 g screen (mg/dl at 1 hr) 
 
 
 
 
_________________________________ 
 
Date:                            GA: 
3 Hr GTT results (if done) 
 (mg/dl at 0,1,2 and 3 hrs) 
 
 
 
 
_________________________________ 
 
Date:                            GA: 
Gestational Diabetes diagnosed      yes   no  
SUPPLEMENT INTAKE DATA 
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PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
   
 
 
Ethnicity 
(Check one box) 
o African-American  
o Asian-American 
o Hispanic  
o European-American (other than 
Hispanic):  
o Other_____________________ 
 
Initial Hgb (at 1st OB appt):_________ 
 
2
nd
 Hgb (at 28 week lab):__________ 
 
Date:___________________ 
 
Date:___________________ 
 
Was an additional iron supplement 
prescribed during pregnancy? 
 yes   no  
Date:___________________ 
Separate iron supplements taken 
during pregnancy 
 yes   no  
If yes, frequency: ______________________ 
Prenatal Vitamins taken during 
pregnancy 
*if just prescribed, complete at subsequent visit 
or by phone interview 
 yes   no  
If yes, name of supplement:    ____________ 
 
Approximate date started:  ______________ 
 
Gestational Age at start of intake:_________ 
 
Intake frequency: ______________________ 
Was an additional DHA supplement 
taken during pregnancy? 
 yes   no  
If yes, name of supplement: ______________  
 
Dose:________    Start Date:______________ 
Vitamin supplements  
prior to pregnancy 
 yes   no  
If yes, what: _______________________ 
Other nutritional supplements 
prior to pregnancy 
 yes   no  
If yes, what: _______________________ 
 
 
Date enrolled:  ______/_____/_____ 
                mmm/dd/yyyy 
 
Age Group – (check one) 
 
16 – 25.99    Group I   _______      26 – 35.99 Group II _________ 
 
 
Date of Initial Capsule Dispensing:   ____/_____/_____ 
                           mmm/dd/yyyy  
Pregnancy Study Protocol  University of Kansas Medical Center 
Susan Carlson PhD,  Investigator  Kansas City, KS 
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TEST PRODUCT ACCOUNTABILITY 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
  
 
 
 
 
 
Week  
0 
Week 
4 
Week 
 8 
Week 
12 
Week 
20 
Week  
24 
Week 
30 
Week 
 ____ 
Total 
Date Delivered to 
Patient 
(mmm/dd/yyyy) 
 
         
Number of 
Capsules 
100 
 
100 100 100 100 100 100 100  
 
 
Date Returned 
from Patient 
 
 
 
        
 
Number of 
Capsules Returned 
 
         
 
Total Capsules 
Consumed 
     By 
Count  
         
          
   *Total Capsules 
Consumed 
                Interview 
         
*To be completed by study personnel ongoing or at completion of pregnancy. The Investigational Pharmacy will 
complete the remaining info 
 on an identical form with the same subject identifier 
 
 
# of Weeks in Treatment Phase:________  (Date of Enrollment:__________ to Date of 
Delivery:__________) 
 
*Total Study Capsule Intake: ____________ 
 
*Average Number of Capsules Consumed per Week:  __________ 
Pregnancy Study Protocol    University of Kansas Medical Center 
Susan Carlson PhD, Investigator  Kansas City, KS 
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LABORATORY 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
  
 
 
 
 Maternal Blood at Enrollment:    yes   no 
 
 Date & Time: ____/_____/_____     ________ 
            mmm/dd/yyyy                       hh:mm 
 
Maternal Blood Postnatally:   yes   no 
 
 Date & Time: ____/_____/_____    ________ 
          mmm/dd/ yyyy         hh:mm 
 
Cord Venous Blood    yes   no  
 
Date & Time: ____/_____/_____     ________ 
               mmm/dd/yyyy                          hh:mm 
 
  
Maternal RBC Phospholipid DHAat Enrollment:                __________ 
(grams per 100 grams of total fatty acids) 
 
Materal RBC Phospholipid DHA Postnatal :                       __________ 
(grams per 100 grams of total fatty acids) 
 
Cord RBC Phospholipid DHA         ____________ 
(grams per 100 grams of total fatty acids) 
 
Pregnancy Study Protocol    University of Kansas Medical Center 
Susan Carlson PhD, Investigator  Kansas City, KS 
 
69 
 
DELIVERY 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
  
 
 
 
Date of Delivery: ____/____/______     Time of Delivery: ________  
    mmm/dd/yyyy)                     (hh:mm) 
 
Gestational Age at Delivery: _____   Maternal Weight at Delivery: _____Pounds 
 
Weight gain enrollment to delivery     ______ Pounds 
 
Delivery Type:  C-Section    Vaginal 
       
If C-Section, reason: ____________________________________________ 
 
If vaginal:    Spontaneous  Augmented    Induced  
 
Did patient go into labor on her own?        Yes   No 
 
Estimated Blood Loss recorded in labor and delivery chart: _______cc 
 
Infant gender:___________ Apgar at 1 min.: _____ Apgar at 5 min.: _____ 
  
Birth Weight: ____________ (g)    Length: ________ cm 
 
Head Circumference: ___________cm  
 
Low Birth Weight (< 2500 grams):        Yes   No 
 
Size for Gestational Age:    SGA       AGA      LGA 
  
Preterm (< 37 weeks):      Yes         No      GA at delivery:_____ 
 
Meconium in Amniotic Fluid:    Yes         No 
  
Infant transfer to NICU:     Yes         No 
 
 
Pregnancy Study Protocol    University of Kansas Medical Center 
Susan Carlson PhD, Investigator  Kansas City, KS 
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***Full Contact Log to be printed at time of delivery from G:\users\Scarlson\ 
Research Group\DHA Pregnancy Study\Contact Logs and Contact Info *** 
 
 
PATIENT CONTACT INFORMATION 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
  
 
 
  
Scheduled 
Week 
 
Date/Time 
Telephone Comments (include all 
nonroutine contacts by phone/letter in 
same 4 wk-period and denote as NR) 
 
 
Week 4 
 
_____/_____/_____ 
(mmm/dd/yyyy) 
 
____________ 
(24 hour clock hh:mm) 
 
 
 
 
Week 8 
 
_____/_____/_____ 
(mmm/dd/yyyy) 
 
____________ 
(24 hour clock hh:mm) 
 
 
 
Week 12 
 
_____/_____/_____ 
(mmm/dd/yyyy) 
 
____________ 
(24 hour clock hh:mm) 
 
 
 
Week 16 
 
_____/_____/_____ 
(mmm/dd/yyyy) 
 
____________ 
(24 hour clock hh:mm) 
 
 
 
Week 20 
 
_____/_____/_____ 
(mmm/dd/yyyy) 
 
____________ 
(24 hour clock hh:mm) 
 
 
 
Week 24 
_____/_____/_____ 
(mmm/ddyyyy) 
____________ 
(24 hour clock hh:mm) 
 
 
Week 30 
_____/_____/_____ 
(mmm/dd/yyyy) 
____________ 
(24 hour clock hh:mm) 
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CONCOMITANT MEDICATIONS 
PATIENT 
NUMBER 
PATIENT INITIALS DATE 
  
 
 
 
Medication 
(Generic or Trade Name) 
Date Reason 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
   
   
   
 Check this box if this is last page of Concomitant Medications 
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ADVERSE EXPERIENCES 
PATIENT 
NUMBER 
PATIENT INITIALS DATE  
  
 
 
 
 Did the patient have any adverse experiences since consuming study 
supplement?      Yes    No 
 
 
 
Adver
se 
Event 
Code 
by 
Body 
Syste
m 
 
Adverse Event 
Description 
 
 
 
(One event per line)  
(Underlying conditions 
only;   
do not list procedures) 
Was  
Adve
rse 
Even
t 
Serio
us? 
 
 
 
1=Ye
s 
   
2=No 
Date of 
Onset 
 
 
 
 
 
___/___/
_____ 
mm  dd  
yyyy 
Date 
Stopped 
 
 
 
 
 
 
___/___/
_____ 
mm  dd  
yyyy 
O 
N 
G 
O 
I 
N 
G 
 
Intens
ity 
 
 
 
 
 
1=Mild 
2=Mod
erate 
3=Seve
re 
Relatio
nship    
        To   
 
Treatm
ent 
 
1=Not 
Related 
2=Possibl
y Rel     
3=Probab
ly Rel 
4=Definit
ely     
    
Related 
          Action 
Taken 
 
 
1=No Action 
Taken 
2=Regimen  
    
Adjusted/Interrupte
d 
3=Regimen 
Discontinued 
4=Concomitant 
Medication 
5=Non-Drug 
Therapy  
  
Outc
ome 
 
 
 
 
1=Ong
oing 
2=Res
olved 
3=Dea
th 
4=Unk
nown 
 
 
 
 
 
 
 
    
 
    
 
 
 
 
 
 
 
    
 
    
 
 
 
 
 
 
 
    
 
    
 
___________________________________________________            _____/______/_____                
Investigator’s Signature                                                           Date     (mmm/dd/yyyy) 
 
 Check this box if this is last page of Adverse Experiences 
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INVESTIGATOR CONFIDENCE AND SIGN-OFF 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
  
 
 
 
To be Answered At Completion of Study  
 
 
Has the patient been employed within the past year?  
 
If YES, occupation: _____________________________ 
 
Does patient intend to return to work or begin work before baby is 18 months 
of age? 
 
Have any phone numbers or address changed? If so, get new info 
 
Phone number and name of person who can always contact them 
 
How long has person had this phone number (if only a short time seek another 
contact) 
 
Did the patient have any concerns about the study or product? If so, what 
were the concerns?  
 
 
INVESTIGATOR SIGN-OFF 
 
 
I have reviewed the data in the Case Report Form.   
By signing below, I confirm that it is accurate and complete. 
 
 
          
Investigator Signature     Date (mmm/dd/yyyy) 
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FOOD AND SUPPLEMENTS INTAKE QUESTIONNAIRE 
PATIENT NUMBER PATIENT INITIALS DATE 
   
How often and what amount does the patient eat of the following foods? 
FOOD     
(ENTER 
AMOUNT IN 
APPROPRIAT
E COLUMN) 
Never 1 time 
per  
Month 
2-3 
times 
per 
Month 
1 time 
per 
Week 
2-3 
times 
per 
Week 
3-4 
times 
per 
Week 
5-6 
times 
per 
Week 
Every 
day 
2 or 
more 
times 
per 
Day 
Eggs          
Oysters          
Shellfish 
(shrimp, 
scallops, crab) 
         
Tuna, salmon, 
or other ocean 
fish 
(including 
sardines or 
herring) 
         
Catfish or lake 
fish (state kind) 
         
Fish sandwich          
Tuna salad or 
casserole 
         
Chicken or beef 
liver or 
liverwurst 
         
Beef alone          
Beef as part of a 
mixed dish 
         
Chicken          
Chicken as part 
of a mixed dish 
         
Pork          
Pork as part of a 
mixed dish 
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